描述接受玻璃体内抗血管内皮生长因子注射治疗的患者对侧眼新生血管性年龄相关性黄斑变性的进展情况。
Characterizing Progression to Neovascular AMD in Fellow Eyes of Patients Treated With Intravitreal Anti-VEGF Injections.
出版信息
Ophthalmic Surg Lasers Imaging Retina. 2021 Mar;52(3):123-128. doi: 10.3928/23258160-20210302-02. Epub 2021 Mar 1.
BACKGROUND AND OBJECTIVE
The purpose of this study was to assess the real-world incidence of conversion to bilateral neovascular age-related macular degeneration (nAMD) following treatment initiation of nAMD in the initial eye.
PATIENTS AND METHODS
This was a retrospective cohort of electronic health records from retinal centers across the United States (Vestrum Database) of all patients with unilateral nAMD treated with anti-vascular endothelial growth factor therapy.
RESULTS
A total of 22,553 patients with unilateral nAMD were included. Fellow eyes of 8,522 patients (38%) converted to nAMD. Among these, 2,639 (12%), 2,030 (9%), and 1,802 (8%) patients converted in Years 1, 2, and 3, respectively, after diagnosis in the first eye. Fellow eyes had better vision at conversion and 1 year following conversion.
CONCLUSIONS
The fellow eye should be monitored at regular intervals to detect signs of neovascularization. Fellow eyes presented with significantly better vision at diagnosis than the initial eye and maintained better visual acuity with less injections. .
背景与目的
本研究旨在评估在初始眼接受新生血管性年龄相关性黄斑变性（nAMD）治疗后，双侧 nAMD 实际转化率。
患者与方法
本研究为回顾性队列研究，分析了美国各地视网膜中心的电子健康记录（Vestrum 数据库）中所有接受抗血管内皮生长因子治疗的单侧 nAMD 患者。
结果
共纳入 22553 例单侧 nAMD 患者。8522 例患者（38%）的对侧眼发生 nAMD。其中，2639 例（12%）、2030 例（9%）和 1802 例（8%）患者分别在第 1、2 和 3 年诊断出第一只眼后发生了 nAMD。对侧眼在转归时和转归后 1 年的视力更好。
结论
应定期监测对侧眼，以发现新生血管化的迹象。与初始眼相比，对侧眼在诊断时视力明显更好，且注射次数更少，视力保持更好。
Zotero 插件